Should we use risk selection tests for HPV 16 and/or 18 positive cases: comparison of p16/Ki67 and cytology
Karolina Mazurec1, Martyna Trzeszcz1,2*, Maciej Mazurec1, Joanna Streb3, Agnieszka Halon4, Robert Jach5
1 Corfamed Woman’s Health Center, Kluczborska 37, 50-322 Wroclaw, Poland; carlos.mazurec@icloud.com (K.M.); m.mazurec@corfamed.pl (M.M.)2 Division of Pathology and Clinical Cytology, University Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland; m.trzeszcz@corfamed.pl (M.T.)3 Department of Oncology, Jagiellonian University Medical College, Kopernika 50, 31-501 Krakow, Poland; joanna.streb@uj.edu.pl (J.S.)4 Department of Clinical and Experimental Pathology, Division of Clinical Pathology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; agnieszka.halon@umed.wroc.pl (A.H.)5 Division of Gynecologic Endocrinology, Jagiellonian University Medical College, Kopernika 23, 31-501 Krakow, Poland; jach@cm-uj.krakow.pl (R.J.)
*Corresponding author
Correspondence to: Martyna Trzeszcz, MD, PhD, Division of Pathology and Clinical Cytology, University Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland; m.trzeszcz@corfamed.pl (M.T.); +48508646805
Conflicts of Interest : Robert Jach has given a lecture sponsored by the Roche company. The other authors declare no conflict of interest.
Funding : This research received no external funding.
Ethics Statement : The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Jagiellonian University (opinion ID 118.6120.36.2023).
Shortened title : Should we use triage tests for HPV 16/18+ cases?